Time discrimination: a comparison between healthy controls, unmedicated schizophrenics, zotepine-treated schizophrenics and schizophrenics treated with conventional neuroleptics

被引:0
|
作者
Ulferts, J [1 ]
Meyer-Lindenberg, A [1 ]
Gallhofer, B [1 ]
机构
[1] Univ Giessen, Zentrum Psychiat, D-35385 Giessen, Germany
关键词
zotepine; schizophrenia; time discrimination;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
In a cross-sectional study time discrimination performance was examined of healthy controls, unmedicated schizophrenics, zotepine-treated schizophrenics, and schizophrenics treated with conventional neuroleptics (haloperidol, fluphenacine). There were no significant differences among the groups in age and gender, the schizophrenic groups were not significantly different in BPRS-score and cumulative length of stay. The medication of the patients treated with neuroleptics was given in equipotent doses. Statistics was performed by ANOVA and subsequent Least Significant Difference (LSD) Test. In relation to the healthy controls a significant impairment of time perception of unmedicated schizophrenic patients as well as conventionelly treated schizophrenic patients could be demonstrated, but not of patients treated with zotepine. Further, unmedicated and conventionally treated patients showed a significant impairment in time estimation compared to patients treated with zotepine. The study shows an illness-related impairment among schizophrenics with a positive effect of zotepine on time discrimination performance. The receptor binding profiles of the various drugs as likely cause of these differences are discussed.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 28 条
  • [21] DIFFERENCES IN P3 AMPLITUDES BETWEEN SCHIZOPHRENICS AND HEALTHY CONTROLS VARY BETWEEN THE DIFFERENT EVENTS PRESENTED IN A GUESSING TASK
    VERLEGER, R
    BODE, M
    AROLT, V
    WASCHER, E
    KOMPF, D
    NEUROPSYCHOBIOLOGY, 1994, 30 (2-3) : 114 - 123
  • [22] A COMPARISON OF PLATELET MONOAMINE-OXIDASE ACTIVITY AND PHOSPHATIDYLSERINE CONTENT BETWEEN CHRONIC PARANOID SCHIZOPHRENICS AND NORMAL CONTROLS
    OROLOGAS, AG
    BUCKMAN, TD
    EIDUSON, S
    NEUROSCIENCE LETTERS, 1986, 68 (03) : 293 - 298
  • [23] Serotonin receptor densities in neuroleptic naive schizophrenics, unmedicated depressed patients and healthy controls: An in vivo analysis using 18-F-setoperone and positron emission tomography
    Ngan, ETC
    Yatham, LN
    Liddle, PF
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 244 - 244
  • [24] Comparison of IL-13 and IL-27 levels between schizophrenics and healthy subjects before and after antipsychotic administration
    Alidadi, Ali
    Khazaei, Hossein Ali
    Shahraki, Babak Nakhjavan
    Andarzi, Salar
    Jalili, Arman
    Mirzaei, Ali
    Shahraki, Ali
    Hajinejad, Salah
    Hashemi, Seyed Mehdi
    INTERNATIONAL JOURNAL OF MEDICAL RESEARCH & HEALTH SCIENCES, 2016, 5 (09): : 654 - 661
  • [25] LONGITUDINAL THERAPEUTIC COMPARISON BETWEEN 2 PROTOTYPIC NEUROLEPTICS (HALOPERIDOL AND CHLORPROMAZINE) IN MATCHED GROUPS OF SCHIZOPHRENICS - NONTHERAPEUTIC INTERACTIONS WITH TRIHEXYPHENIDYL - THEORETICAL IMPLICATIONS FOR POTENCY DIFFERENCES
    SINGH, MM
    KAY, SR
    PSYCHOPHARMACOLOGIA, 1975, 43 (02): : 115 - 123
  • [26] Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine
    Yu, YWY
    Tsai, SJ
    Yang, KH
    Lin, CH
    Chen, MC
    Hong, CJ
    NEUROPSYCHOBIOLOGY, 2001, 43 (02) : 79 - 82
  • [27] Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban-treated patients and healthy controls
    Evrard, Jonathan
    Siriez, Romain
    Bouvy, Celine
    Favresse, Julien
    Yildiz, Halil
    Hainaut, Philippe
    Mullier, Francois
    Dogne, Jean-Michel
    Douxfils, Jonathan
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (07)
  • [28] Comparison of follicular T helper cells, monocytes, and T cells priming between newly diagnosed and rituximab-treated MS patients and healthy controls
    Yahyazadeh, Sheida
    Esmaeil, Nafiseh
    Shaygannejad, Vahid
    Mirmosayyeb, Omid
    RESEARCH IN PHARMACEUTICAL SCIENCES, 2022, 17 (03) : 315 - 323